[Adjuvant bevacizumab and cetuximab for stage III colon cancer: why such failure in an adjuvant situation?].
Université Pierre-et-Marie-Curie, Assistance publique-Hôpitaux de Paris, hôpital Saint-Antoine, service d’oncologie médicale, Inserm U938, 184, rue du Faubourg-Saint-Antoine, 75571 Paris Cedex 12, France. thierry.andre@sat.aphp.fr
Thierry
T
André
Annette K
AK
Larsen
Aimery
A
de Gramont
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D061206:Neoplasm Micrometastasis / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab